Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults

뉴스 본문을 불러오고 있어요.

Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults | 웨이프 WAPE

Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults

기사 요약

관련 종목

댓글 —